414 results on '"Mitsikostas, Dimos D."'
Search Results
2. Nocebos in migraine
3. A Prospective, Observational Study Assessing Effectiveness, Safety, and QoL of Greek Patients with Multiple Sclerosis Under Treatment with Fingolimod
4. Meta-analysis of placebo-arm dropouts in osteoporosis randomized-controlled trials and implications for nocebo-associated discontinuation of anti-osteoporotic drugs in clinical practice
5. Nocebo-associated treatment discontinuation with subcutaneous anti-osteoporotic drugs. A systematic review and meta-analysis of placebo-arm dropouts in randomized-controlled trials
6. Disease-modifying treatments for multiple sclerosis have not affected the incidence of neoplasms in clinical trials over 3 decades: a meta-analysis with meta-regression
7. Current and Emerging Treatment Options in Pediatric Onset Multiple Sclerosis
8. Depression and Anxiety Symptoms in Headache Disorders: An Observational, Cross-Sectional Study
9. Placebo responses vary by route of administration in migraine prevention trials. What does this mean?
10. Understanding frontal lobe function in epilepsy: Juvenile myoclonic epilepsy vs. frontal lobe epilepsy
11. COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study
12. Diagnosis and management of migraine in ten steps
13. Nocebo in Headache Treatment
14. Implications of Placebos and Nocebos in Clinical Practice
15. Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis
16. Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial
17. Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study
18. A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study
19. Therapies targeting CGRP signaling for medication overuse headache
20. Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial.
21. Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies
22. Tension-type headache
23. Lateralization of Insular Ischemic Stroke is Not Associated With Any Stroke Clinical Outcomes: The Athens Stroke Registry
24. Headache Attributed to Reversible Cerebral Vasoconstriction Syndrome (RCVS)
25. IncobotulinumtoxinA for the Treatment of Blepharospasm in Toxin-Naïve Subjects: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial
26. New players in the preventive treatment of migraine
27. Nocebo in multiple sclerosis trials: A meta-analysis on oral and newer injectable disease-modifying treatments
28. Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: a meta-analysis
29. Placebo and Nocebo Effects
30. Are indirect comparisons for treatments in migraine necessitas? Many inevitable challenges to overcome
31. Rimegepant for migraine: acute efficacy beyond the USA
32. Nocebos in rheumatology: emerging concepts and their implications for clinical practice
33. Comparing the efficacy of disease-modifying therapies in multiple sclerosis
34. Chapter 13 - Evidence-based symptomatic treatment of migraine
35. Triptans attenuate capsaicin-induced CREB phosphorylation within the trigeminal nucleus caudalis: a mechanism to prevent central sensitization?
36. Making headway — a role for CGRP in post-traumatic headache
37. Responder Rates With Eptinezumab Over 24 Weeks in Patients With Prior Migraine Preventive Treatment Failures (S47.007)
38. Effectiveness of Fremanezumab for the Preventive Treatment of Migraine: Second Interim Analysis of the Observational PEARL Study (P12-12.002)
39. The evolution of comprehensive genetic analysis in neurology: Implications for precision medicine
40. The 5-HT1F receptor as the target of ditans in migraine — from bench to bedside.
41. Nocebo in Headache Treatment
42. Implications of Placebos and Nocebos in Clinical Practice
43. Headache in Systemic Diseases
44. Refractory burning mouth syndrome: clinical and paraclinical evaluation, comorbidities, treatment and outcome
45. The nocebo phenomenon in the COVID-19 pandemic: a nocebodemic effect
46. sj-pdf-1-cep-10.1177_03331024231184909 - Supplemental material for The prevalence and burden of medication overuse headache in Greece
47. sj-pdf-2-cep-10.1177_03331024231184909 - Supplemental material for The prevalence and burden of medication overuse headache in Greece
48. Male and female sex hormones in primary headaches
49. Current perspectives on the recognition and diagnosis of low CSF pressure headache syndromes
50. B-Cell Targeted Therapies in Patients with Multiple Sclerosis and Incidence of Headache: A Systematic Review and Meta-Analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.